Regeneron Announces Upcoming Investor Conference Presentations

Date : 04/29/2019 @ 9:01PM
Source : PR Newswire (US)
Stock : Regeneron Pharmaceuticals, Inc. (REGN)
Quote : 299.42  1.05 (0.35%) @ 12:09AM

Regeneron Announces Upcoming Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Historical Stock Chart

3 Months : From Apr 2019 to Jul 2019

Click Here for more Regeneron Pharmaceuticals, Inc. Charts.

TARRYTOWN, N.Y., April 29, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations as follows:

  • Bank of America Merrill Lynch 2019 Healthcare Conference at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) on Wednesday, May 15, 2019
  • Barclays 2019 Biopharmaceuticals CEO/CFO Conference Call Series at 11:00 a.m. Eastern Time on Friday, May 17, 2019
  • UBS 2019 Global Healthcare Conference at 10:00 a.m. Eastern Time on Monday, May 20, 2019

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations.  Replays of the conference call and webcasts will be archived on the Company's website and will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:
Investor Relations
Mark Hudson
914.847.3482
mark.hudson@regeneron.com

Corporate Communications
Hala Mirza
914.847.3422
hala.mirza@regeneron.com

Cision View original content:http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-investor-conference-presentations-300839896.html

SOURCE Regeneron Pharmaceuticals, Inc.

Copyright 2019 PR Newswire

Latest REGN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.